---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-25-000034"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:17:40.307731+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Recursion reports Q4 net loss $178.9M, FY2024 net loss $463.7M; cash runway into 2027

## Summary
- Cash, cash equivalents and restricted cash $603.0M at Dec 31, 2024 vs $401.4M at Dec 31, 2023; runway extended into 2027.
- Q4 revenue $4.5M (down 59% YoY); FY2024 revenue $58.8M (up 32% YoY). Pro forma revenue $82.6M.
- Operating cash outflow $115.4M in Q4; $359.2M for FY2024. Exscientia cash burn ~$184M pre-acquisition.
- Completed Exscientia merger Nov 2024; maintaining guidance of at least $100M in annual synergies.
- Pipeline advanced: REC-617 showed durable partial response; three new clinical trials initiated (DAHLIA, TUPELO, ALDER).

## SEC filing metadata
- accession: 0001601830-25-000034
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000034/0001601830-25-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000034/rxrx-20250228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-25-000034
- JSON: https://secwatch.observer/filing/0001601830-25-000034.json
- Plain text: https://secwatch.observer/filing/0001601830-25-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.